Mechanisms of Atrial Pathoelectrophysiology in HCM
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorGuy's and St Thomas' NHS Foundation Trust
About this trial
This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual.
Researchers will study electrical signals from the heart and advanced heart imaging. By doing this, they hope to better understand how AF behaves in people with HCM and why treatments may not work as well for them.
The information from this study may help improve future treatments for people who have both HCM and AF.
Eligibility criteria
Qualifiers
Paroxysmal or persistent atrial fibrillation
Diagnosis of hypertrophic cardiomyopathy
Patient planning to proceed to atrial fibrillation ablation following clinical consultation
Age 18-80 years
Disqualifiers
Any clinical contra-indication to ablation
Any disease limiting life expectancy to <1 year
Potential participant currently pregnant or breast feeding
Contraindication to MRI including renal dysfunction (eGFR<30ml/min)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
40 Participants
are grouped into 1 trial groupSponsors and collaborators
Guy's and St Thomas' NHS Foundation Trust
Lead sponsor
King's College London
Collaborator
Source ClinicalTrials.gov